BRIEF-Alloy Therapeutics Announces Target Specific Collaboration & License Agreement For Use Of Anticlastic Antisense Platform With Sanofi

Reuters
01-08

Jan 7 (Reuters) - ALLOY THERAPEUTICS:

* ALLOY THERAPEUTICS: ANNOUNCES A TARGET SPECIFIC COLLABORATION & LICENSE AGREEMENT FOR USE OF ANTICLASTIC ANTISENSE PLATFORM WITH SANOFI

* ALLOY THERAPEUTICS: SANOFI TO PROVIDE ALLOY WITH UPFRONT LICENSE FEES & NEAR-TERM PRECLINICAL MILESTONE PAYMENTS UP TO $27.5 MILLION

* ALLOY THERAPEUTICS: UNDER AGREEMENT, ALLOY ALSO ELIGIBLE TO RECEIVE DISCOVERY, DEVELOPMENT, AND COMMERCIAL MILESTONE PAYMENTS OF OVER $400 MILLION

Source text: Further company coverage:

((Reuters.Briefs@thomsonreuters.com;))

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10